The ruling is a modest positive for Corcept as it gains limited CEO-level testimony that could support its causation defense, but the core antitrust case (Teva v. Corcept over mifepristone for Cushing's syndrome) remains active. Monitor the Francis deposition (due by Aug 5, 2026) and any subsequent summary judgment motions for material developments.
Price Chart
Executive Summary
Corcept won a limited discovery ruling in its antitrust defense against Teva Pharmaceuticals. The court granted Corcept permission to depose Teva's CEO Richard Francis for up to 2 hours regarding his critique of Teva's mifepristone strategy, but denied Corcept's broader requests to depose him on pricing/distribution and to collect his custodial documents. This is a modest procedural victory for Corcept—it gains some ammunition to argue Teva's generic mifepristone failed due to Teva's own choices, not Corcept's conduct—but the substance of the underlying antitrust case remains unresolved.
Court Ruling Details
Key Facts
- Court granted Corcept permission to depose Teva CEO Richard Francis for up to 2 hours on his critique of Teva's mifepristone strategy and possible solutions
- Court denied Corcept's requests to depose Francis on pricing, distribution strategy, and to collect his custodial documents
- The ruling does not resolve the underlying antitrust claims; it is a discovery-level procedural order
- No damages were awarded, no injunction issued, and the case continues
Financial Impact
No financial impact quantified in the ruling; pure procedural discovery order
Risk Factors
- The underlying antitrust case remains unresolved—a loss could still carry financial or behavioral remedies
- Limited scope of deposition may not yield the admissions Corcept needs
- Appeal or escalation by Teva on procedural grounds is possible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-10e56aaee5-CORT |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | Insider Cluster | $113.88 $115.63 | ▲ +1.54% | ▲ +1.28% | $116.49 (+2.29%) |
Aug 28, 2026 5w ago | Insider Cluster | $113.88 $116.10 | ▲ +1.95% | ▲ +1.44% | $116.49 (+2.29%) |
Aug 27, 2026 5w ago | Insider Cluster | $116.93 $117.00 | ▲ +0.06% | ▲ +0.16% | $116.49 (−0.38%) |
Aug 20, 2026 6w ago | Insider Cluster | $121.05 $114.86 | ▼ −5.11% | ▼ −5.11% | $116.49 (−3.77%) |
Aug 18, 2026 6w ago | Insider Cluster | $118.10 $111.85 | ▲ +5.29% | ▲ +4.30% | $116.49 (+1.36%) |
Aug 12, 2026 7w ago | Insider Cluster | $112.18 $114.92 | ▲ +2.44% | ▲ +4.34% | $116.49 (+3.84%) |
Aug 12, 2026 7w ago | Insider Cluster | $112.18 $114.92 | ▲ +2.44% | ▲ +4.34% | $116.49 (+3.84%) |
Aug 6, 2026 8w ago | Insider Cluster | $110.77 $111.62 | ▲ +0.77% | ▲ +1.16% | $116.49 (+5.16%) |
Aug 5, 2026 8w ago | Insider Cluster | $107.95 $112.80 | ▲ +4.49% | ▲ +3.89% | $116.49 (+7.91%) |
Jul 23, 2026 10w ago | Court Ruling | $96.66 $121.05 | ▲ +25.23% | ▲ +21.92% | $116.49 (+20.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access